{"nctId":"NCT02102204","briefTitle":"Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis","startDateStruct":{"date":"2014-03-25","type":"ACTUAL"},"conditions":["Hyperparathyroidism, Secondary"],"count":902,"armGroups":[{"label":"Etelcalcetide","type":"EXPERIMENTAL","interventionNames":["Drug: Etelcalcetide"]}],"interventions":[{"name":"Etelcalcetide","otherNames":["KAI-4169","AMG 416","Parasabiv"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject has provided informed consent prior to initiation of any study-specific activities/procedures\n* Subject has completed treatment in Study 20120231 (also known as KAI-4169-008) or Study 20120360, or has participated in Study 20120334 (also known as KAI-4169-005-01)\n* Female subjects who are: post-menopausal (post-menopausal is defined as no menses for the previous 1 year and over the age of 50 years), surgically sterilized, have a medical condition that prevents pregnancy, remain abstinent, or are willing to use an acceptable method of effective contraception during the study and for 3 months after the last dose. Women of child-bearing potential (WOCBP) must have a negative serum pregnancy test within 2 weeks prior to the first dose of AMG 416 in the current study\n* Subject must be receiving hemodialysis 3 or 4 times weekly for at least 3 months\n\nExclusion Criteria:\n\n* Currently receiving treatment in another investigational device or drug study (other than in one of the designated parent studies)\n* Subject has known sensitivity to any of the products or components to be administered during dosing\n* Subject has been prescribed cinacalcet by the primary nephrologist between the conclusion of the parent study and the start of dosing with AMG 416 in the current study\n* Subject is receiving dialysis prescription dialysate calcium concentration \\< 2.25 mEq/L\n* Subject is pregnant or nursing","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"110 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Adverse Events","description":"A serious adverse event is an AE that met at least 1 of the following criteria:\n\n* fatal\n* life threatening\n* required in-patient hospitalization or prolongation of existing hospitalization\n* resulted in persistent or significant disability/incapacity\n* congenital anomaly/birth defect\n* other medically important serious event.\n\nThe relationship of each AE to study treatment was assessed by the investigator.\n\nThe following AE grading scale was used:\n\nMild: Transient or mild discomfort; no limitation in activity; no medical intervention/therapy required Moderate: Mild to moderate limitation in activity-some assistance may be needed; no or minimal medical intervention/therapy required Severe: Marked limitation in activity, some assistance usually required; medical intervention/therapy required, hospitalization possible Life-threatening: Extreme limitation in activity, significant assistance required, significant medical intervention/therapy required, hospitalization probable.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"768","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"436","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"287","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"123","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"219","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"324","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Parathyroid Hormone Levels Between Two to Nine-times the Upper Limit of Normal","description":"The percentage of participants who maintained plasma parathyroid hormone (PTH) levels within the Kidney Disease Improving Global Outcomes (KDIGO) recommended range of not less than 2x the upper limit of normal (ULN) and not greater than 9x the ULN at months 6, 12, and 18, with the ULN based on the reference range of the assay used at the individual clinical site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Serum Phosphorus â‰¤ the ULN","description":"Percentage of participants with serum phosphorus less than or equal to the upper limit of normal for the assay used.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Serum Corrected Calcium < 7.5 mg/dL","description":"The percentage of participants with serum corrected calcium (cCa) reported for cumulative time intervals from day 1 through months 6, 12, and 18, using the participant's lowest recorded corrected calcium value during the time interval.\n\nIf serum albumin was less than 4.0 g/dL, serum calcium was corrected according to the following formula:\n\ncCa (mg/dL) = total calcium (mg/dL) + (4 - albumin \\[g/dL\\])\\*0.8. If serum albumin was \\> 4.0 g/dL no correction was made.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Shifts From Baseline Grade 0 or 1 to Postbaseline Grade 3 or 4 for Laboratory Parameters","description":"The Common Terminology Criteria for Adverse Events (CTCAE) grades for laboratory parameter values were defined based on the upper/lower limit of normal from the local laboratories contracted by the study centers.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Developed Positive Binding Anti-Etelcalcetide Antibodies","description":"The number of participants who were binding antibody positive post-baseline with a negative or no result at baseline (where baseline for participants previously treated with etelcalcetide is Day 1 of the first study in which they were exposed to etelcalcetide and for participants previously treated with cinacalcet is the ending time point for study 20120360).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"111","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":436,"n":884},"commonTop":["Blood calcium decreased","Diarrhoea","Hyperphosphataemia","Muscle spasms","Hypertension"]}}}